-
Featured Authors
-
Archives
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Business and Investments
Latest From Business and Investments
A What Would George Do? Tribute
For those of you who have been attending BIO events over the past few years, you’ve not only come to know the One-on-One Partnering System, but BIO staff as well. In particular, our Partnering Guru George MacDougall, – the very person our blog is named after! Recently, George accepted a position at another DC non-profit and is moving on from BIO. In honor of all his hard work, exceptional customer service, and contributions to the Read More >
BIO Investor Forum Company Snapshot: Immune Design
In the third installment of the Investor Forum Company Snapshots, hear from Immune Design Corp. The CEO of the company, Dr. Carlos Paya, will be presenting next week at the 10th Annual BIO Investor Forum on Tuesday afternoon. Company Snapshot What are the short-term and long-term priorities for your company? Short term: focus on validating in patients a product from each of our two novel technologies. We will be conducting testing of : 1) An Read More >
Medical Innovation at Risk
The National Venture Capital Association’s MedIC Coalition recently released a report showing U.S. venture capitalists are decreasing their investments in biopharmaceutical and medical device companies, reducing their concentration in prevalent disease areas and shifting investments towards Europe and Asia. The report, Vital Signs: The Threat to Investment in U.S. Medical Innovation and the Imperative of FDA Reform, strongly indicates that America’s medical innovation economy is in grave danger of losing its primary source of funding, Read More >
Perspective on Market Valuation for Biotech Drug Developers
Of the 300 publicly traded U.S. biotechs, 219 (73%) are developing drugs. The other 27% are working on molecular tools, diagnostics, biofuels, and other biotech endeavors. One question that is often asked with respect to drug-focused biotechs is: How big are they compared to traditional pharmaceutical companies? How many are valued as small start-ups vs large, or mid-size pharmas? It turns out that more than half the sector trades with a market valuation of less Read More >
Boosting Investment in Biotech
The President’s Council on Jobs and Competitiveness issued an interim report with suggestions to increase job creation and growth in the U.S., as well as plans for encouraging investment in the industry. Of particular interest to the biotech industry, the report offers suggestions for streamlining the FDA approval process. The report also outlines ideas for eliminating capital gains on investments of $25 million or less that are held for at least five years and recommends Read More >
